论文部分内容阅读
目的 :比较观察低分子肝素 (LMWH)和尿激酶 (UK)治疗不稳定性心绞痛 (UAP)的疗效和不良反应。方法 :92例UAP患者随机分成LMWH组、UK组和常规治疗 (RT)组 ,疗程 1周 ,观察 12周。结果 :1周后总有效率 ,LMWH组91.18%、UK组 92 .85 %、RT组 70 % ,均与RT组对比P <0 .0 5 ;观察 12周LMWH组无 1例发生急性心肌梗死 (AMI)、UK组发生 4例AMI,2例猝死 ,两组对比P <0 .0 5 ,RT组发生 1例AMI。无 1例发生严重出血并发症。结论 :在常规治疗基础上加用LMWH和UK治疗UAP均能有效控制UAP发作 ,但是UK组AMI发生率上升 ,且不良反应多 ,故前者更安全有效
Objective: To compare the efficacy and adverse reactions of low molecular weight heparin (LMWH) and urokinase (UK) in the treatment of unstable angina pectoris (UAP). Methods: Ninety-two patients with UAP were randomly divided into LMWH group, UK group and conventional therapy (RT) group. The course of treatment was 1 week and the observation was for 12 weeks. Results: After 1 week, the total effective rate was 91.18% in LMWH group, 92.85% in UK group and 70% in RT group, all of which were compared with RT group (P <0.05). No acute myocardial infarction occurred in 1 LMWH group (AMI). There were 4 AMI cases in the UK group and 2 sudden death cases (P <0.05). There was 1 AMI in the RT group. No one had severe bleeding complications. CONCLUSIONS: Urap plus LMWH and UK in the treatment of UAP can effectively control the onset of UAP on the basis of routine treatment. However, the incidence of AMI in the UK group increases with more adverse reactions, so the former is safer and more effective